المؤلفون: Liping Zhang (177396), Emily C. Cherney (8904614), Xiao Zhu (257280), Tai-an Lin (10218930), Johnni Gullo-Brown (2387257), Derrick Maley (10048683), Kathy Johnston-Allegretto (10218933), Lisa Kopcho (5941772), Mark Fereshteh (6508499), Christine Huang (743871), Xin Li (51274), Sarah C. Traeger (1622287), Gopal Dhar (8394876), Aravind Anandam (8394879), Sandeep Mahankali (10218936), Shweta Padmanabhan (4067707), Prabhakar Rajanna (8779820), Venkata Murali (10218939), Thanga Mariappan (10218942), Robert Borzilleri (2102530), Gregory Vite (2853350), John T. Hunt (1601446), Aaron Balog (1371318)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Pharmacology, Biotechnology, Developmental Biology, Cancer, Hematology, Virology, Space Science, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, phase III, metastatic melanoma, Potent Inhibitors, cell carcinoma, variety, BMS, imidazopyridine-containing IDO 1 in., IDO 1 inhibitors, IDO 1 inhibitor, small-molecule immunotherapy, heterocyclic isosteres, Indoleamine, IDO 1-selective inhibitor

Relation: https://figshare.com/articles/journal_contribution/Discovery_of_Imidazopyridines_as_Potent_Inhibitors_of_Indoleamine_2_3-Dioxygenase_1_for_Cancer_Immunotherapy/14141796

الاتاحة: https://doi.org/10.1021/acsmedchemlett.1c00014.s001